NCT02997423 is a clinical trial in Glioblastoma, sponsored by University of Iowa.

Who is sponsoring NCT02997423?

NCT02997423 is sponsored by University of Iowa.

What condition does NCT02997423 study?

NCT02997423 studies Glioblastoma.

Is NCT02997423 still recruiting?

NCT02997423 is currently completed. Last updated 13 February 2023.

Last reviewed 2023-02-13 · How we verify

NCT02997423

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)

Completed Last updated 13 February 2023

What this trial tests

trial in Glioblastoma in 153 participants. Completed in 30 November 2022.

Timeline

30 November 2016

Primary endpoint
30 November 2022

30 November 2022

Quick facts

Lead sponsor	University of Iowa
Status	Completed
Study type	OBSERVATIONAL
Enrollment	153
Start date	30 November 2016
Primary completion	30 November 2022
Estimated completion	30 November 2022
Sites	19 locations across United States

Conditions studied

Glioblastoma — all drugs for Glioblastoma →

Sponsor

University of Iowa

Who can join

21 and older, any sex, with Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-institutional, consortium-based, non-interventional prospective blinded endpoints clinical study to determine whether high activity of Cytochrome C Oxidase (CcO) in tumor specimens from subjects with newly diagnosed primary GBM is associated with shortened OS (primary outcome) and PFS (secondary outcome) times.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Adenosine triphosphate induced cell death: Mechanisms and implications in cancer biology and therapy.
Zhang HL, Sandai D, Zhang ZW, Song ZJ, et al · · 2023 · cited 11× · PMID 38179405 · DOI 10.5306/wjco.v14.i12.549
Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials.
Cudkowicz M, Chase MK, Coffey CS, Ecklund DJ, et al · · 2020 · cited 8× · PMID 32202612 · DOI 10.1001/jamaneurol.2020.0367
Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial.
Griguer CE, Oliva CR, Coffey CS, Cudkowicz ME, et al · · 2022 · cited 3× · PMID 35088051 · DOI 10.1093/noajnl/vdab186
Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications.
Akter S, Madhuvilakku R, Kar AK, Nila IS, et al · · 2026 · PMID 41881983 · DOI 10.1038/s41392-026-02583-x

Verify or expand the search:

Other recruiting trials for Glioblastoma

Currently open trials in the same condition.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other University of Iowa trials

Trials by the same sponsor.

NCT07224269 — Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis · EARLY_PHASE1 · not yet recruiting
NCT07244809 — Probing the Role of Mitochondrial Oxidative Stress in Impaired Vascular Function Among Young Adults With Early Life Adve · NA · recruiting
NCT07097961 — Paediatric Post-TB Pulmonary Rehab Study · NA · recruiting
NCT06951594 — Robotic-Assisted Versus Manual Electrode Array Insertion · NA · recruiting
NCT06710119 — Effect of Custom Dynamic Orthoses on Forefoot Loading · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02997423 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Iowa
Last refreshed: 13 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02997423.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing